Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs INCY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INCY Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

INCY Overall Winner 6-Pillar Tally: MXCT 1 – 5 INCY Matrix Metrics: MXCT 2 – 8 INCY

As of Nov 20, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas INCY carries 54.6/100 (HOLD) at $114.62 (13.3x Forward P/E, 32.2% operating margin).

  • Growth vs. Quality Trade-Off: INCY earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. MXCT 41.7/100 SELL) and 0.30β · 31% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile INCY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs INCY
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
INCY NASDAQ Head-to-Head Winner
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
$114.62
-1.07% 1D
Market Cap $23.6B
TTM Revenue $6.01B
Forward P/E 13.3x
Beta / 30D Vol 0.30β · 31% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 59.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 42
RSI-14: 41.8 · SMA20: $118.84 · SMA50: $118.49

6-Pillar Scorecard Institutional Category Breakdown (MXCT 1 – 5 INCY)

Columns: Metric · MXCT · INCY
1. Valuation Multiples INCY
Forward P/E N/M 13.3x
Trailing P/E N/M 59.1x
PEG Ratio N/M 10.82x
EV / Revenue 3.9x 3.4x
2. Growth & Scale INCY
Revenue Growth (YoY) +48.7% +14.0%
Earnings Growth (YoY) +0.0% +37.7%
TTM Revenue (USD) $34M $6.01B
Market Cap $132.2M $23.6B
3. Profitability & Quality INCY
Gross Margin 81.0% 56.0%
Operating Margin -85.5% 32.2%
Net Profit Margin -81.4% 6.7%
Return on Equity (ROE) -16.9% 7.8%
4. Balance Sheet & Cash Flow INCY
Cash Generation (TTM) -$24M $680M
Cash Flow Margin -69.2% 11.3%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $3.24B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 40.7% (37th %ile)
Put/Call OI Skew N/A 0.67x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat INCY
OpEx & R&D Intensity N/A 23.8% of Rev ($1.43B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (2) vs INCY (8)
Institutional Metric MXCT INCY Criterion Row Edge
Market Capitalization
Scale
$132.2M $23.6B Larger Scale INCY
Trailing P/E Ratio
Valuation
N/M 59.1x Lower Multiple INCY
Forward P/E Ratio
Valuation
N/M 13.3x Lower Multiple INCY
Revenue Growth (YoY)
Growth
+48.7% +14.0% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-85.5% 32.2% Higher Margin INCY
Net Profit Margin
Profitability
-81.4% 6.7% Higher Margin INCY
Return on Equity (ROE)
Capital Efficiency
-16.9% 7.8% Higher ROE INCY
52-Week Range Position
Momentum
63% ($1–$2) 58% ($89–$133) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 0.30β · 31% Vol Lower Realized Risk INCY
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 54.6 / 100 (HOLD) Higher Composite INCY
Trailing 12M Revenue (USD)
Operating Scale
$34M $6.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 56.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev 10.82x PEG · 3.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) $680M ($3.24B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INCY +2.23 pp
MXCT: -4.2% · INCY: -1.97%
3M Horizon MXCT +9.0 pp
MXCT: -1.44% · INCY: -10.44%
6M Horizon MXCT +13.75 pp
MXCT: +31.73% · INCY: +17.98%
1Y Horizon INCY +32.54 pp
MXCT: -19.41% · INCY: +13.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue INCY Revenue MXCT Op. Margin INCY Op. Margin Margin Leader
FY2018 N/A $1.88B N/A 6.9% INCY
FY2019 $10M $2.16B -93.7% 18.6% INCY
FY2020 $20M $2.67B -71.6% -9.9% INCY
FY2021 $20M $2.99B -84.3% 19.6% INCY
FY2022 $30M $3.39B -95.2% 17.1% INCY
FY2023 $20M $3.70B -247.7% 16.8% INCY
FY2024 $20M $4.24B -230.5% 1.4% INCY
FY2025 $20M $5.14B -247.6% 29.5% INCY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INCY CONSOLIDATION
82d in phase · OBV DISTRIBUTION
Current IV 40.7%
IV Percentile 37th %ile
Put/Call OI Skew 0.67x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact INCY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $120.27 · IV 46.3%

INCY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($12,027)

Compare $12,027 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 46.3% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $120 / $130 Bull Call Spread

Buy 1x $120C · Sell 1x $130C · 31d

Net Entry $380 Debit
T+5d @ +5% Move +$140 (+37%)
Max Risk / Buffer $380 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $110 / $105 Bull Put Spread

Sell 1x $110P · Buy 1x $105P · 31d

Net Entry $178 Credit
Max Credit / Yield +$178 (+55.3% RoM)
Max Risk / Buffer -10.0% Cushion ($322 Mgn)
5d Edge & Liquidity 75% PoP · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Dec 18 $105P / $120-$130C Seagull

Sell 1x $105P · Buy 1x $120/$130C · 31d

Net Entry $245 Debit
T+5d @ +5% Move +$229 (+16.1% RoM)
Max Risk / Buffer -12.7% Put Cushion ($1,430 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INCY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $23.6B market capitalization and 32.2% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($1.43B)
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs INCY Key Questions & Quantitative Answers

As of Nov 20, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas INCY carries 54.6/100 (HOLD) at $114.62 (13.3x Forward P/E, 32.2% operating margin). Growth vs. Quality Trade-Off: INCY earns the overall head-to-head edge with a stronger Unified Composite Score (54.6/100 HOLD vs. MXCT 41.7/100 SELL) and 0.30β · 31% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile INCY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INCY leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with INCY at +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MXCT cumulative revenue shifted +100.0% while INCY shifted +173.4%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 23.8% of Rev ($1.43B) (0 disclosures) for INCY.

INCY screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas INCY trades at 13.3x Forward P/E, 59.1x Trailing P/E, 10.82x PEG, and 3.4x EV/Revenue (11.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus INCY (7.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, INCY carries 40.7% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 0.67x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.